Patterns of levels of biological metals in CSF differ among neurodegenerative diseases

We measured the levels of some biological metals: copper (Cu), iron (Fe), magnesium (Mg), manganese (Mn), and zinc (Zn) in the cerebrospinal fluid (CSF) in patients with neurodegenerative diseases (52 patients with amyotrophic lateral sclerosis (ALS)), 21 patients with Alzheimer's disease (AD), and 20 patients with Parkinson's disease (PD) by inductively coupled plasma mass spectrometry (ICP-MS). The diagnoses were additionally supported by neuroimaging techniques for AD and PD. In ALS, the levels of Mg (p<0.01 significant difference), Fe, Cu (p<0.05), and Zn (p<0.10) in CSF were higher than those in controls. Some patients showed very high levels of Cu and Zn before the critical deterioration of the disease. In AD, the levels of Cu and Zn in CSF were significantly higher in patients with late-onset AD (p<0.01). In PD, we found significantly increased levels of especially Cu and Zn in particular (p<0.01) and Mn (p<0.05) in CSF. A multiple comparison test suggested that the increased level of Mg in ALS and that of Mn in PD were the pathognomonic features. These findings suggest that Cu and Zn in particular play important roles in the onset and/or progression of ALS, AD, and PD. Therefore, Cu-chelating agents and modulators of Cu and Zn such as metallothionein (MT) can be new candidates for the treatment of ALS, AD, and PD.

[1]  M. Nordberg,et al.  Separation of proteins including metallothionein in cerebrospinal fluid by size exclusion HPLC and determination of trace elements by HR-ICP-MS , 2007, Brain Research.

[2]  E. D. Harris.  Basic and clinical aspects of copper. , 2003 .

[3]  K. Ishige,et al.  Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis , 2008, Experimental Neurology.

[4]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[5]  G. Lees,et al.  Zinc Metabolism in the Brain: Relevance to Human Neurodegenerative Disorders , 1997, Neurobiology of Disease.

[6]  V. Haroutunian,et al.  Elevated cortical zinc in Alzheimer disease , 2006, Neurology.

[7]  S. Orimo,et al.  123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[8]  G. Sancesario,et al.  Metal changes in CSF and peripheral compartments of parkinsonian patients , 2006, Journal of the Neurological Sciences.

[9]  J. Hwang,et al.  Accumulation of labile zinc in neurons and astrocytes in the spinal cords of G93A SOD-1 transgenic mice , 2009, Neurobiology of Disease.

[10]  E. Londos,et al.  CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies , 2009, Neurobiology of Aging.

[11]  P. Pasqualetti,et al.  Longitudinal prognostic value of serum “free” copper in patients with Alzheimer disease , 2009, Neurology.

[12]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[13]  Y. Hayashi,et al.  High Levels of Copper, Zinc, Iron and Magnesium, but not Calcium, in the Cerebrospinal Fluid of Patients with Fahr's Disease , 2010, Case Reports in Neurology.

[14]  Kazuo T. Suzuki,et al.  Copper accumulation and compartmentalization in mouse fibroblast lacking metallothionein and copper chaperone, Atox1. , 2009, Toxicology and applied pharmacology.

[15]  E. Kapaki,et al.  Trace elements, age, and sex in amyotrophic lateral sclerosis disease , 1997, Biological Trace Element Research.

[16]  K. Talbot,et al.  Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS , 2008, Progress in Neurobiology.

[17]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[18]  Takashi Asada,et al.  Voxel-based morphometry to discriminate early Alzheimer's disease from controls , 2005, Neuroscience Letters.

[19]  M. Mayer,et al.  Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones , 1984, Nature.

[20]  H Matsuda,et al.  Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. , 2007, AJNR. American journal of neuroradiology.

[21]  D R Rajput,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[22]  K. Blennow,et al.  Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid , 2009, Neurobiology of Aging.

[23]  Sachiko Takahama,et al.  Magnesium deficiency over generations in rats with special references to the pathogenesis of the parkinsonism–dementia complex and amyotrophic lateral sclerosis of Guam , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[24]  M. Yamada,et al.  Metallothioneins and Neurodegenerative Diseases , 2004 .